Status:

UNKNOWN

Cardiorenal Effecs of Losartan in Kidney Transplant Recipients

Lead Sponsor:

Medical University of Gdansk

Collaborating Sponsors:

Medical University of Warsaw

Pomeranian Medical University Szczecin

Conditions:

Renal Transplant Failure

Cardiovascular Complication

Eligibility:

All Genders

18-65 years

Brief Summary

The influence of Losartan to cardiovascular and renal outcomes in patients after renal transplatation.

Detailed Description

The benefits of cardio and nephroprotective properties of treatment with drugs blocking the renin angiotensin aldosterone system in the general population has already been shown. There are no data on ...

Eligibility Criteria

Inclusion

  • 740 patients, either sex, either non-diabetic or diabetic who underwent the kidney transplantation and who:
  • Are at least three months post-transplantation
  • Have hypertension.
  • Have an estimated glomerular filtration rate greater than or equal to 30 ml/min/1.73 m2

Exclusion

  • Pregnant or the possibility of becoming so and breast feeding.
  • Angioedema from an Angiotensin Converting Enzyme (ACE) inhibitor or Angiotensin Receptor Blocker (ARB) in the history.
  • Serum potassium greater than 5.5 mmol/l on two or more occasions in the preceding three months.
  • Graft artery stenosis (i.e. psv of more than 200 cm/s in doppler usg)
  • Left ventricular dysfunction that requires an ACE inhibitor or an ARB
  • New immunosuppressive agent was started or previous immunosuppressant stopped in the three months prior to study entry or plan to switch immunosuppressive agents within next three months.
  • Currently on four or more blood pressure pills and have an average blood pressure over three visits greater than 150/100.
  • Currently on an ACE-inhibitor or an ARB or treatment with an ACE inhibitor or ARB after kidney transplantation lasted more than 3 months.
  • Had an acute coronary syndrome, episode of malignant hypertension, stroke or transient ischaemic attack in the three months prior to study entry.

Key Trial Info

Start Date :

September 1 2015

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2023

Estimated Enrollment :

740 Patients enrolled

Trial Details

Trial ID

NCT05243446

Start Date

September 1 2015

End Date

December 31 2023

Last Update

February 17 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Medical University

Gdansk, Poland, 80-952